1300 856 695
+44 203 514 0688
1800 867 1390If you would like to submit a blog post for consideration, please email admin@healthcert.com
Research Review on Dermatology [February 1]
Highlights in the February research review on dermatology include the encouraging findings from two phase 3 trials (published as a single paper in New Engl J Med) of dupilumab, a monoclonal antibody, in the treatment of moderate-to-severe AD (atopic dermatitis), and also for the Janus kinase inhibitor tofacitinib for treating severe alopecia areata. Authors from Denmark have reported increased 10-year mortality in patients who had been hospitalised for AD (but not as much as those hospitalised for psoriasis), likely because of more cardiovascular comorbidities often present in patients with severe AD. This issue concludes with a paper reporting some success with 308nm excimer light therapy in a small series of patients with treatment-resistant alopecia universalis.
Featured in this issue:
- Two phase 3 dupilumab trials for AD
- Re-examining the threshold for re-excision of transected dysplastic nevi
- Skin cancer in nonwhite organ transplant recipients
- β-HPV associated with cutaneous SCC in immunocompetent individuals
- Tofacitinib for severe alopecia areata and variants
- Olumacostat glasaretil for acne vulgaris
- Hospitalisation for AD increases mortality
- Low-dose isotretinoin for seborrhoea/seborrhoeic dermatitis
- Ustekinumab in severe AD
- 308nm excimer light therapy for alopecia universalis
Click here to download the full paper
Interested in General Dermatology?
The HealthCert Professional Diploma of General Dermatology will teach you how to manage all major dermatological conditions in primary care. The courses are university quality-assured, CPD-accredited and count towards multiple Master degree pathways and clinical attachment programs in Australia and overseas. The program is delivered online.
1300 856 695
+44 203 514 0688
1800 867 1390
